Proactive research analyst Robin Davison speaks to Thomas Warner after publishing a 2023 Clinical Outlook for clinical stage biotechnology company Tiziana Life Sciences Ltd (NASDAQ:TLSA).
He gives his take on what the market can expect from the business this year, saying that it is now “moving forward quite nicely.”
#ProactiveInvestors #TLSA #biotech #tiziana #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
source